NEW YORK (GenomeWeb News) – Rosetta Genomics said today that it has received accreditation from the College of American Pathologists' Laboratory Accreditation Program.
The cancer molecular diagnostic testing company has labs in Philadelphia and in Israel.
Through those labs, the company offers a test for identifying primary tumors in metastatic cancers and in patients with cancers of unknown primary origin; a test that identifies the squamous sub-type of non-small cell lung cancer; and a test that differentiates mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung and pleura.
The CAP accreditation program is based on standards recognized by the federal government as being equal to the government's inspection program, Rosetta Genomics said, and it is based on an onsite inspection that includes operations, assay validation, and testing procedures.
"An accreditation from CAP indicates compliance with the most demanding good laboratory procedures and indicates that the laboratory meets or exceeds regulatory requirements," Rosetta Genomics CEO and President Kenneth Berlin said in a statement.